EyePoint Pharmaceuticals Inc. (EYPT)
Summary
EyePoint, Inc. (EYPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
EyePoint, Inc. (EYPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
EyePoint Pharmaceuticals Eyes Transformative 2026 as DURAVYU Phase 3 Data Nears
Eyepoint Pharmaceuticals NASDAQ: EYPT executives said the company remains on track to report top-line data from its Phase 3 wet age-related macular degeneration program for DURAVYU, also known as EYP-1901, beginning in August, with a second pivotal trial expected to follow about two months later.
EyePoint, Inc. (EYPT) Q1 2026 Earnings Call Transcript
EyePoint, Inc. (EYPT) Q1 2026 Earnings Call Transcript
EyePoint Pharmaceuticals Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 80 | $752.8 | $1,098.06 | $345.26 | 45.86% |
| BG Bart Gancher Intech Investment Management LLC | 18,660 | $113,162.28 | $254,195.85 | $141,033.57 | 124.63% |
 Winthrop Advisory Group Winthrop Advisory Group LLC | 10,100 | $130,189 | $134,330 | $4,141 | 3.18% |
 David Kim Paradigm Biocapital Advisors LP | 3.14M | $51.54M | $42.89M | -$8.65M | -16.78% |
 Joseph Castro Nuveen LLC | 260,276 | $2.98M | $3.52M | $538,935.89 | 18.06% |
EyePoint Pharmaceuticals Inc. (EYPT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has EyePoint Pharmaceuticals Inc. ever had a stock split?
EyePoint Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jay S. Duker CEO | NASDAQ (NMS) Exchange | 30233G209 CUSIP |
| US Country | 214 Employees | - Last Dividend | 11 Jun 2008 Last Split | 27 Jan 2005 IPO Date |
Overview
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for patients suffering from serious retinal diseases. Utilizing its proprietary bioerodible Durasert E technology, the company endeavors to offer sustained intraocular drug delivery solutions. Originating as pSivida Corp. before rebranding to EyePoint Pharmaceuticals in March 2018, the company has been advancing its mission since its inception in 1987. Headquartered in Watertown, Massachusetts, EyePoint Pharmaceuticals is committed to leveraging its technological innovations to address the unmet medical needs of patients with retinal disorders.
Products and Services
-
EYP-1901
This lead product candidate represents a significant advancement in the treatment of VEGF-mediated retinal diseases. EYP-1901 combines vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with EyePoint's Durasert E technology for sustained delivery. Currently, it is in Phase 2 clinical trials targeting conditions such as wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). This investigational treatment underscores the company's commitment to addressing the complexities of retinal diseases through innovative sustained delivery mechanisms.
-
EYP-2301
Another promising pipeline program, EYP-2301, harnesses the Durasert E technology to formulate a TIE-2 agonist. This approach is aimed at improving outcomes in serious retinal diseases by potentially offering a novel mechanism of action. While still under development, EYP-2301 exemplifies EyePoint Pharmaceuticals' ongoing exploration of diverse therapeutic avenues to meet the varied challenges posed by retinal diseases.
